Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HEXO HEXO	$0.71 +2.5%	$0.87	$0.66 ▼ $3.84	$31.24M	1.35	880,508 shs	305,500 shs
LABS MediPharm Labs	C$0.08	C$0.07	C$0.06 ▼ C$0.12	C$31.13M	0.88	305,155 shs	89,155 shs
MPH Medicure	C$1.05 -8.7%	C$1.17	C$0.63 ▼ C$1.27	C$10.96M	0.9	4,261 shs	266 shs
VIR Vir Biotechnology	$4.38 +0.3%	$5.18	$4.16 ▼ $14.45	$607.76M	1.18	1.56 million shs	897,940 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HEXO HEXO	0.00%	0.00%	0.00%	0.00%	0.00%
LABS MediPharm Labs	0.00%	0.00%	+7.14%	+7.14%	+7.14%
MPH Medicure	0.00%	-8.70%	-5.41%	+11.70%	-1.87%
VIR Vir Biotechnology	-2.68%	0.00%	-19.41%	-3.33%	-50.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HEXO HEXO	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LABS MediPharm Labs	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MPH Medicure	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	3.3445 of 5 stars	3.4	2.0	0.0	0.0	2.9	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HEXO HEXO	0.00	N/A	N/A	N/A
LABS MediPharm Labs	0.00	N/A	N/A	N/A
MPH Medicure	0.00	N/A	N/A	N/A
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	591.43% Upside

Current Analyst Ratings Breakdown

Latest MPH, HEXO, VIR, and LABS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
5/22/2025	VIR Vir Biotechnology	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HEXO HEXO	$146.20M	0.21	N/A	N/A	$2.44 per share	0.29
LABS MediPharm Labs	C$39.42M	0.79	C$0.06 per share	1.30	C$0.11 per share	0.68
MPH Medicure	C$21.08M	0.52	C$0.42 per share	2.49	C$1.91 per share	0.55
VIR Vir Biotechnology	$14.39M	42.23	N/A	N/A	$6.82 per share	0.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HEXO HEXO	-$845.90M	-$5.21	N/A	N/A	N/A	-235.33%	-74.04%	-32.51%	N/A
LABS MediPharm Labs	-C$12.05M	-C$0.03	N/A	∞	N/A	-30.56%	-24.41%	-7.17%	N/A
MPH Medicure	-C$2.03M	-C$0.19	N/A	∞	N/A	-9.65%	-10.18%	-5.63%	N/A
VIR Vir Biotechnology	-$521.96M	-$4.00	N/A	N/A	N/A	-2,895.94%	-50.22%	-40.78%	10/30/2025 (Estimated)

Latest MPH, HEXO, VIR, and LABS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.72	-$0.80	-$0.08	-$0.80	$2.38 million	$1.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HEXO HEXO	N/A	N/A	N/A	N/A	N/A
LABS MediPharm Labs	N/A	N/A	N/A	N/A	N/A
MPH Medicure	N/A	2.24%	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HEXO HEXO	0.01	0.41	0.24
LABS MediPharm Labs	1.45	3.21	3.10
MPH Medicure	4.65	2.03	1.29
VIR Vir Biotechnology	N/A	7.01	7.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HEXO HEXO	7.78%
LABS MediPharm Labs	0.71%
MPH Medicure	23.10%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
HEXO HEXO	4.69%
LABS MediPharm Labs	4.45%
MPH Medicure	26.68%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HEXO HEXO	1,277	44.00 million	41.93 million	Optionable
LABS MediPharm Labs	130	415.00 million	N/A	Not Optionable
MPH Medicure	N/A	10.44 million	N/A	Not Optionable
VIR Vir Biotechnology	580	138.92 million	116.69 million	Optionable

MPH, HEXO, VIR, and LABS Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Tejara Capital Ltd

August 17 at 6:45 AM | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for VIR Earnings

August 12, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Outlook for VIR Earnings

August 12, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month Low - Here's Why

August 10, 2025 | marketbeat.com

Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)

August 9, 2025 | theglobeandmail.com

Short Interest in Vir Biotechnology, Inc. (NASDAQ:VIR) Rises By 50.7%

August 9, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% Following Weak Earnings

August 8, 2025 | marketbeat.com

Vir Biotechnology Reports Q2 2025 Financial Results

August 7, 2025 | msn.com

Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum

August 7, 2025 | msn.com

Vir (VIR) Q2 Revenue Drops 61%

August 7, 2025 | fool.com

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6, 2025 | businesswire.com

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 6, 2025 | businesswire.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $109,780.00 in Stock

August 5, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Brokerages

August 1, 2025 | marketbeat.com

Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks

July 31, 2025 | genengnews.comG

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025 | businesswire.com

Allianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MPH, HEXO, VIR, and LABS Company Descriptions

HEXO NYSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.

MediPharm Labs TSE:LABS

C$0.08 0.00 (0.00%)

As of 03:44 PM Eastern

MediPharm Labs Corp, along with its subsidiaries, produces purified, pharmaceutical-like cannabis extracts and related derivative products. The company generates revenue from Private label, White label, the Tolling process, and others. Some of its vape brands are Northern Lights, Blue Dream Pink Kush and GG4. Its geographical segments are Canada and Australia.

Medicure CVE:MPH

C$1.05 -0.10 (-8.70%)

As of 08/18/2025 09:30 AM Eastern

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Vir Biotechnology NASDAQ:VIR

$4.38 +0.02 (+0.34%)

Closing price 03:59 PM Eastern

Extended Trading

$4.42 +0.04 (+1.03%)

As of 04:15 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time